Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBF-Cord conditioning for high-risk myeloid malignancies
NCT02333838Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2015
- Primary completion
- May 2018
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of thiotepa, busulfan, fludarabine, antithymocyte globulin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Assistance publique - Hôpitaux de Paris. Status: unknown.
02
Drugs
thiotepabusulfanfludarabineantithymocyte globulin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02333838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333838.